Loxapine information

Loxapine
Clinical data
Trade names	Loxitane, Adasuve
AHFS/Drugs.com	Monograph
MedlinePlus	a682311
License data	EU EMA: by INN; US DailyMed: Loxapine; US FDA: Loxapine;
Routes of; administration	By mouth, inhalation, intramuscular
Drug class	Antipsychotic
ATC code	N05AH01 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); BR: Class C1 (Other controlled substances); US: WARNINGRx-only; EU: Rx-only;
Pharmacokinetic data
Protein binding	96.8%
Metabolism	Extensive Liver; active metabolites include amoxapine and 8-hydroxyloxapine. Inhibits P-gp and is a substrate of CYP1A2, CYP3A4 and CYP2D6
Elimination half-life	4 hours (oral); 7.61 hours (inhalation)
Excretion	Majority are excreted within 24 hours, main route through urine (conjugated metabolites), small amounts through the feces (unconjugated metabolites)
Identifiers
	IUPAC name 8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine;
CAS Number	1977-10-2 ;
PubChem CID	3964;
IUPHAR/BPS	205;
DrugBank	DB00408 ;
ChemSpider	3827 ;
UNII	LER583670J;
KEGG	D02340 ;
ChEBI	CHEBI:50841 ;
ChEMBL	ChEMBL831 ;
CompTox Dashboard (EPA)	DTXSID7023229 ;
ECHA InfoCard	100.016.215
Chemical and physical data
Formula	C18H18ClN3O
Molar mass	327.81 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	109 to 110 °C (228 to 230 °F)
	SMILES Clc2ccc1Oc4c(/N=C(\c1c2)N3CCN(C)CC3)cccc4;
	InChI InChI=1S/C18H18ClN3O/c1-21-8-10-22(11-9-21)18-14-12-13(19)6-7-16(14)23-17-5-3-2-4-15(17)20-18/h2-7,12H,8-11H2,1H3 ; Key:XJGVXQDUIWGIRW-UHFFFAOYSA-N ;
	(what is this?) (verify)

Bottle containing loxapine capsules, a mid-potency antipsychotic.

Loxapine, sold under the brand names Loxitane and Adasuve (inhalation only) among others, is a tricyclic^[4] antipsychotic medication used primarily in the treatment of schizophrenia. The medicine is a member of the dibenzoxazepine class and structurally very similar to clozapine. Several researchers have argued that loxapine, initially classified as a typical antipsychotic, behaves as an atypical antipsychotic.^[5]

Loxapine may be metabolized by N-demethylation to amoxapine, a tricyclic antidepressant.^[6]

^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
^ ^a ^b ^c Truven Health Analytics, Inc. DrugPoint System (Internet) [cited 2013 Sep 21]. Greenwood Village, CO: Thomsen Healthcare; 2013.
^ Popovic D, Nuss P, Vieta E (2015-04-01). "Revisiting loxapine: a systematic review". Annals of General Psychiatry. 14: 15. doi:10.1186/s12991-015-0053-3. PMC 4391595. PMID 25859275.
^ Glazer WM (1999). "Does loxapine have "atypical" properties? Clinical evidence". The Journal of Clinical Psychiatry. 60 (Suppl 10): 42–46. PMID 10340686.
^ Cheung SW, Tang SW, Remington G (March 1991). "Simultaneous quantitation of loxapine, amoxapine and their 7- and 8-hydroxy metabolites in plasma by high-performance liquid chromatography". Journal of Chromatography. 564 (1): 213–221. doi:10.1016/0378-4347(91)80083-O. PMID 1860915.

[FDA-AllBoxedWarnings-1] "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.

[2] Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.

[DrugPoint-3] Truven Health Analytics, Inc. DrugPoint System (Internet) [cited 2013 Sep 21]. Greenwood Village, CO: Thomsen Healthcare; 2013.

[4] Popovic D, Nuss P, Vieta E (2015-04-01). "Revisiting loxapine: a systematic review". Annals of General Psychiatry. 14: 15. doi:10.1186/s12991-015-0053-3. PMC 4391595. PMID 25859275.

[pmid10340686-5] Glazer WM (1999). "Does loxapine have "atypical" properties? Clinical evidence". The Journal of Clinical Psychiatry. 60 (Suppl 10): 42–46. PMID 10340686.

[pmid1860915-6] Cheung SW, Tang SW, Remington G (March 1991). "Simultaneous quantitation of loxapine, amoxapine and their 7- and 8-hydroxy metabolites in plasma by high-performance liquid chromatography". Journal of Chromatography. 564 (1): 213–221. doi:10.1016/0378-4347(91)80083-O. PMID 1860915.

Loxapine information

and 28 Related for: Loxapine information

Loxapine

Dopamine antagonist

Amoxapine

Tetracyclic antidepressant

Crystal polymorphism

Tetracyclic

CR gas

Cocaine

Dorothea Puente

Quetiapine

List of psychotropic medications

Sedative

Antihistamine

Mirtazapine

MDMA

Intermittent explosive disorder

List of psychiatric medications

Aripiprazole

Brazilian Controlled Drugs and Substances Act

Ketamine

Chlorphenamine

Promethazine

Hydroxyzine

Psilocybin

Trazodone

Beta blocker

Salbutamol

Diphenhydramine